A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 593 participants.

Also called NCT03578809

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 593 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03578809
Other papers using this trial's data
  • Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B Circulation, 2022-09-20 DOI, PubMed 36039762

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Brazil, Czechia, Hungary, Israel, Netherlands, Poland, Russia, Slovakia, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03578809. Randomized; triple masking; primary purpose treatment. Start 2018-06-05 (actual); primary completion 2021-01-18 (actual). Results posted on 2022-02-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction
Acronym
REAL-TIMI 63B
Condition
ST Elevation Myocardial Infarction
Intervention (Biological)
MEDI6012
Intervention (Other)
Placebo
Lead sponsor
MedImmune LLC (class: industry)
Collaborator
The TIMI Study Group (class: other)

Record details

Record id
cardio:ct-nct03578809
Content hash
857048fcfbe6db60a2d547f15ca5ee04e6d041aaedad8f2e5ff8d4332283ac03